Clinical Trials Archives

Written by 56gqy

April 26, 2018

Pfizer treats first patient in trial for investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy

Pfizer has stated that they have begun their Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in patients with Duchenne muscular dystrophy (DMD). The first patient received an infusion of the mini-dystrophin gene, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University

Written by 56gqy

March 22, 2018

NIHR unveil new set of standards for public involvement in clinical research

The National Institute for Health Research (NIHR) has launched a set of new national standards for members of the public involved in clinical research, that will be used by organisations across the UK. The six standards aim to provide accurate benchmarks for effective public involvement, alongside indicators against which improvement can be monitored, it said.

Written by Kat McCarthy

February 16, 2018

Report states financially challenged NHS is diverting nurses from Clinical Trials

According to new research, the financial crisis at the NHS has caused cutbacks on critical clinical trials conducted with drug companies on new medicines. Financially challenged hospitals are redirecting nurses away from drug research to make up for the shortfall in doctors and nurses doing clinical work with patients, according to a report in research

Written by Kat McCarthy

September 13, 2017

Trial results show immunotherapy & targeted drugs could stop melanomas returning

Some of the treatments currently used for certain advanced melanomas could be effective in those with an earlier stage of disease after surgery, according to results from two clinical trials. The studies (Checkmate 238 and COMBI-AD) examined an immunotherapy drug and a combination of targeted drugs respectively, the results showed that both types of treatment

Written by Kat McCarthy

April 11, 2017

Scotland first UK nation to routinely offer HIV PrEP along with Psoriasis, MS and CLL treatments

Scotland is set to become the first UK nation to routinely offer HIV pre-exposure prophylaxis to eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada along with four other new therapies to be funded by the NHS. In clinical trials Truvada (emtricitabine/tenofovir disoproxil) was revealed to cut the relative risk of

Written by Kat McCarthy

April 5, 2017

GW Pharmaceuticals gains orphan status for rare epilepsy cannabinoid Epidiolex

UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy. The approval follows data from two late-stage trials that showed when Epidiolex was added as an adjunct to patients’ current treatment, there was a significant reduction in the

Written by Kat McCarthy

March 16, 2017

New Pfizer antibiotic, Zavicefta launched in UK

Zavicefta has now been launched in the UK to treat serious aerobic Gram-negative infections caused by antibiotic resistant bacteria. The Pfizer drug is a fixed combination of avibactam, a new beta-lactamase inhibitor, and ceftazidime, an antibiotic belonging to the class of third generation cephalosporins which is already approved for use in the EU.

Written by Kat McCarthy

January 18, 2017

AstraZeneca expands their first line cancer immunotherapy programme

AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy. The Phase III MYSTIC trial was originally designed to assess the benefit of durvalumab monotherapy and a combination of durvalumab

Written by Kat McCarthy

January 10, 2017

Allergan increases pipeline with Parkinson’s deal

Allergan has stepped into the field of Parkinson’s disease with an option to acquire US-based neurodegenerative research group Lysosomal Therapeutics (LTI). LTI-291, LTI’s lead programme, is designed to stimulate the activity of glucocerebrosidase (GCase) in the brain, which is reduced in many lysosomal storage diseases because of mutations in the GBA1 gene.

Written by Kat McCarthy

September 13, 2016

AZ initiate trials for using diabetes drug in kidney disease and heart failure

AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga with the aim of exploring its potential beyond the drug’s approved diabetes indication. AZ have initiated two randomised, placebo-controlled Phase IIIb outcome trials assessing Forxiga in the management of chronic kidney disease and chronic heart failure, within participants with and without type-2 diabetes. The

Only Medics

Recruiting Physicians for Pharma

Clinical Trials

Pfizer treats first patient in trial for investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy

NIHR unveil new set of standards for public involvement in clinical research

Report states financially challenged NHS is diverting nurses from Clinical Trials

Trial results show immunotherapy & targeted drugs could stop melanomas returning

Scotland first UK nation to routinely offer HIV PrEP along with Psoriasis, MS and CLL treatments

GW Pharmaceuticals gains orphan status for rare epilepsy cannabinoid Epidiolex

New Pfizer antibiotic, Zavicefta launched in UK

AstraZeneca expands their first line cancer immunotherapy programme

Allergan increases pipeline with Parkinson’s deal

AZ initiate trials for using diabetes drug in kidney disease and heart failure

Like to Talk to a Consultant?